CAGT - Catherine Bollard, MBChB, FRACP, RCPA

Education:
M.B.Ch.B. and M.D., Otago Medical School, New Zealand
Residency and Fellowship, Royal Australasian College of Physicians
Residency and Fellowship, Royal College Pathologists of Australasia
Fellowship, Baylor College of Medicine

Board Certifications:
Royal Australasian College of Physicians (Pediatrics)
Royal College of Pathologists of Australasia (Hematology)

Selected Memberships:
Member, International Society of Cellular Therapy
Inspector, Foundation for the Accreditation of Cellular Therapy
Member of Hodgkin Disease Committee, Children's Oncology Group
Member, American Society of Gene Therapy
Member, American Society of Blood and Marrow Transplantation
Member, American Society of Hematology
Member, Hematology Society of Australia and New Zealand

Editorial Boards:
Bone Marrow Transplantation
Biology of Blood and Marrow Transplant

Clinical Special Interests:
Bone Marrow Transplantation
Cell and Gene Therapy

Research Interests:
Dr. Bollard's research interests involve using cytotoxic T cells (CTL) for viral and malignant diseases. Dr Bollard is a principal investigator on two clinical trials assessing the safety of adoptively transferred donor-derived virus-specific CTL for the prophylaxis and treatment of CMV and adenoviral infection post allogeneic stem cell transplant. She is also evaluating the efficacy of tumor-specific CTL in patients with relapsed EBV positive Hodgkin's disease and non-Hodgkin Lymphoma. Further, she is developing gene therapy strategies to counteract tumor immune evasion mechanisms to enhance the efficacy of adoptive immunotherapy protocols. Specifically, she demonstrated a method of genetically modifying CTL to improve their potential as cell therapy for Hodgkin Disease. The use of CTL expressing a dominant negative TGF beta receptor mutant is likely to improve cell therapy for patients with not only Lymphoma, but also other cancers that use TGF beta secretion as a means to evade the immune response.

Selected Publications:
Ann M. Leen, G. Doug Myers, Uluhan Sili, M. Helen Huls, Heidi Weiss, Kathryn S. Leung, George Carrum, Robert A. Krance, Jeffrey J. Molldrem, Adrian P. Gee, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney, Catherine M. Bollard. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised patients. Nature Medicine. 2006 Oct;12(10):1160-6. Epub 2006 Sep 24

Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE, Leen AM.
Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation.
Bone Marrow Transplant. 2007 Apr 9; [Epub ahead of print]

Kennedy-Nasser AA, Leung K, Mahajan, A, Weiss HL, Arce JA, Gottschalk S, Carrum G, Khan SP, Heslop HE, Brenner MK, Bollard CM, Krance KA. Comparable outcomes of matched related and alternative donor transplants for severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec;12(12):1277-84.

Lacuesta KC, Buza E, Hauser H, Pule M, Brenner MK, Heslop HE, Rooney CM, Bollard CM. “Assessing the Safety of Cytotoxic T Lymphocytes transduced with a dominant negative TGFb Receptor in vivo” J Immunother. 2006 May/June;29(3):250-260

Myers, GD; Heslop, HE; Weiss, H; Kuehnle, I; Demmler, G; Krance, RA; Bollard, CM
Adenovirus Infection Rates in Pediatric Recipients of Alternate Donor Allogeneic Bone Marrow Transplants Receiving Either Anti-Thymocyte Globulin (ATG) or Alemtuzumab. Bone Marrow Transplant. 2005 Dec;36(11):1001-8

Straathof KC, Leen A, Buza E, Brenner MK, Heslop HE, Rooney CM, Bollard CM. “Epitope mapping in CTL derived from patients with type II latency EBV positive tumors” J Immunol. 2005 Sep 15;175(6):4137-47.

Karin C Straathof, Catherine M Bollard, Uday R Popat M Helen Huls, Terisita Lopez, M Craig Morriss, Adrian P Gee, Heidi V Russell, Malcolm K Brenner, Cliona M Rooney and Helen E Heslop. "Virus Specific T cells as Treatment for Nasopharyngeal Carcinoma" Blood, 2005 Mar 1;105(5):1898-904.

Bollard CM, Straathof KC, Huls MH, Lacuesta KC, Brenner MK, Rooney CM, Heslop HE. "The use of EBV-specific Cytotoxtic T cells for EBV+ve Hodgkin Disease". J Exp Medicine, 2004 Dec 20;200(12):1623-33.

Bollard CM, Huls MH, Lacuesta KC, Brenner MK, Rooney CM, Heslop HE. "Generation of autologous LMP2-specific Cytotoxic T cells for patients with relapsed EBV-positive Hodgkin Disease" -J Immunother. 2004 Jul-Aug;27(4):317-27

PJ Amrolia, E Yvon, H Huls, U Sili, E Weider, C Bollard, H Heslop, JJ Molldrem, C Rooney and M K. Brenner. Selective depletion of donor allo-reactive T-cells without loss of anti-viral or anti-leukemic responses. Blood 2003;102(6):2292-9 2003.

CM Bollard, C Rössig, M H Huls, J Massague, MK Brenner, HE Heslop, C M Rooney Reversal of Fortune: Using a TGF-beta-related tumor immune evasion strategy to enhance anti-tumor immunity. Blood 99: 3179-3187, 2002C.

Rossig, CM Bollard, J.G. Nuchtern, CM Rooney, M. K. Brenner. Epstein-Bar virus-specific human T lymphocytes expressing antitumor chimeric T cell receptors: Potential for improved immunotherapy. Blood 90:2009-2016, 2002